LLYEli Lilly and CompanyRunning, no new patients
A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy
Glioma
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 45 (planned)
- Started
- Oct 25, 2024
- Main results expected
- Feb 2027
- Fully finished
- Feb 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Event Free Survival as Determined by Blinded Independent Review Committee
Measured over: Baseline up to approximately 11 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06413706 · record last updated 2026-07-17 · checked 2026-11-09 15:42 UTC